"If that study successfully demonstrates a clinical benefit for PTX-100, the drug could advance directly into another study that could be suitable for registration.Compared to the usual large Phase 3 studies, a comparatively smaller trial might be all that’s needed to register the drug, Prescient says.Yatomi-Clarke says the company is pursuing the quickest route to market for PTX-100 by pursuing areas of unmet clinical need."
Has anybody else noticed this in the * article? Seems quite significant and that the market may have over-reacted about not reaching a phase 2+3 combined trial.
More than 1 way to skin a cat?
"If that study successfully demonstrates a clinical benefit for...
-
- There are more pages in this discussion • 224 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
